Literature DB >> 6428895

The chemosensitivity of a new experimental model--the M5076 reticulum cell sarcoma.

S P Langdon, A Gescher, J A Hickman, M F Stevens.   

Abstract

The M5076 reticulum cell sarcoma is a murine tumour of potential value in experimental chemotherapy. Experiments were conducted to ascertain the growth characteristics and chemosensitivity of this neoplasm in the BDF1 mouse. The intramuscular tumour proved to be responsive to the alkylating agents, nitrosoureas, procarbazine, DTIC and treosulphan, yet insensitive to the antimetabolites and only weakly responsive to adriamycin. Analogues of the antitumour agents hexamethylmelamine and N-methylformamide were tested against this neoplasm. The patterns of activity determined for these analogues against this tumour were identical to those previously reported against other model systems.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428895     DOI: 10.1016/0277-5379(84)90019-1

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  8 in total

1.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes.

Authors:  Z H Siddik; S al-Baker; G Thai; A R Khokhar
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 3.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

4.  Antitumor activity and mechanism of action of the marine compound girodazole.

Authors:  F Lavelle; A Zerial; C Fizames; B Rabault; A Curaudeau
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

5.  The antitumour effect and toxicity of cis-platinum and N-methylformamide in combination.

Authors:  E S Harpur; S P Langdon; S A Fathalla; J Ishmael
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Antitumor and antimetastatic activity of the differentiating agent N-methylformamide in murine tumor systems.

Authors:  M Iwakawa; P J Tofilon; N Hunter; L C Stephens; L Milas
Journal:  Clin Exp Metastasis       Date:  1987 Oct-Dec       Impact factor: 5.150

7.  Effect of cisplatin on primary tumour growth and liver metastases in the M 5076 reticulum sarcoma: implication for new screening modalities.

Authors:  M Schirner; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 8.  Clinical pharmacokinetics of altretamine.

Authors:  G Damia; M D'Incalci
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.